Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMLX Amylyx Pharmaceuticals	$8.34 +0.7%	$5.88	$1.76 ▼ $8.59	$743.44M	-0.49	1.15 million shs	1.13 million shs
AVBP ArriVent BioPharma	$22.05 -2.9%	$21.91	$15.47 ▼ $36.37	$754.40M	1.2	235,563 shs	316,541 shs
IMTX Immatics	$6.00 -3.4%	$5.58	$3.30 ▼ $13.09	$729.30M	0.81	683,311 shs	187,803 shs
KYTX Kyverna Therapeutics	$3.90 -4.2%	$2.98	$1.78 ▼ $10.35	$168.55M	2.95	384,597 shs	170,585 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMLX Amylyx Pharmaceuticals	0.00%	+8.59%	+63.53%	+109.55%	+293.40%
AVBP ArriVent BioPharma	0.00%	+1.94%	-11.41%	+21.55%	+12.21%
IMTX Immatics	0.00%	+0.50%	+2.56%	+40.85%	-51.18%
KYTX Kyverna Therapeutics	0.00%	-3.23%	+34.02%	+109.68%	-62.86%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMLX Amylyx Pharmaceuticals	3.277 of 5 stars	4.5	1.0	2.5	2.5	0.6
AVBP ArriVent BioPharma	2.3834 of 5 stars	4.6	0.0	2.9	0.8	0.0
IMTX Immatics	3.0852 of 5 stars	3.6	4.0	3.5	1.7	0.0
KYTX Kyverna Therapeutics	1.7878 of 5 stars	3.6	2.0	0.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMLX Amylyx Pharmaceuticals	3.00	Buy	$11.75	40.89% Upside
AVBP ArriVent BioPharma	3.14	Buy	$39.29	78.17% Upside
IMTX Immatics	3.20	Buy	$14.67	144.44% Upside
KYTX Kyverna Therapeutics	3.14	Buy	$18.50	374.36% Upside

Current Analyst Ratings Breakdown

Latest KYTX, AMLX, AVBP, and IMTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	AMLX Amylyx Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$10.00
7/10/2025	AVBP ArriVent BioPharma	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy	$33.00
6/24/2025	AMLX Amylyx Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold
6/24/2025	AMLX Amylyx Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
6/24/2025	AMLX Amylyx Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$17.00
6/24/2025	AVBP ArriVent BioPharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$39.00 ➝ $44.00
6/24/2025	AVBP ArriVent BioPharma	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00
6/17/2025	AMLX Amylyx Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
5/30/2025	AMLX Amylyx Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/28/2025	IMTX Immatics	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$10.00
5/27/2025	KYTX Kyverna Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$4.00 ➝ $5.00

(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMLX Amylyx Pharmaceuticals	$87.37M	8.51	N/A	N/A	$2.40 per share	3.48
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	$7.65 per share	N/A
IMTX Immatics	$144.15M	5.06	$0.24 per share	24.56	$5.12 per share	1.17
KYTX Kyverna Therapeutics	N/A	N/A	N/A	N/A	$6.17 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMLX Amylyx Pharmaceuticals	-$301.74M	-$3.11	N/A	N/A	N/A	N/A	-77.21%	-63.84%	8/6/2025 (Estimated)
AVBP ArriVent BioPharma	-$80.49M	-$3.77	N/A	N/A	N/A	N/A	-49.21%	-46.61%	8/13/2025 (Estimated)
IMTX Immatics	$16.47M	-$0.17	N/A	N/A	N/A	-14.73%	-4.52%	-3.34%	8/12/2025 (Estimated)
KYTX Kyverna Therapeutics	-$127.48M	-$3.38	N/A	N/A	N/A	N/A	-51.66%	-45.92%	8/11/2025 (Estimated)

Latest KYTX, AMLX, AVBP, and IMTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	AMLX Amylyx Pharmaceuticals	-$0.43	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q2 2025	AVBP ArriVent BioPharma	-$0.70	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q1 2025	IMTX Immatics	-$0.38	N/A	N/A	N/A	$13.05 million	N/A
8/11/2025	Q2 2025	KYTX Kyverna Therapeutics	-$1.00	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q1 2025	IMTX Immatics	-$0.39	-$0.35	+$0.04	-$0.35	$14.92 million	$20.12 million
5/13/2025	Q1 2025	KYTX Kyverna Therapeutics	-$1.21	-$1.03	+$0.18	-$1.03	N/A	N/A
5/12/2025	Q1 2025	AVBP ArriVent BioPharma	-$0.66	-$1.90	-$1.24	-$1.90	N/A	N/A
5/8/2025	Q1 2025	AMLX Amylyx Pharmaceuticals	-$0.45	-$0.42	+$0.03	-$0.42	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMLX Amylyx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	N/A
IMTX Immatics	N/A	N/A	N/A	N/A	N/A
KYTX Kyverna Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMLX Amylyx Pharmaceuticals	N/A	12.05	12.05
AVBP ArriVent BioPharma	N/A	14.34	14.34
IMTX Immatics	N/A	10.28	10.28
KYTX Kyverna Therapeutics	N/A	7.44	7.44

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMLX Amylyx Pharmaceuticals	95.84%
AVBP ArriVent BioPharma	9.48%
IMTX Immatics	64.41%
KYTX Kyverna Therapeutics	18.08%

Insider Ownership

Company	Insider Ownership
AMLX Amylyx Pharmaceuticals	11.70%
AVBP ArriVent BioPharma	18.58%
IMTX Immatics	3.30%
KYTX Kyverna Therapeutics	22.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMLX Amylyx Pharmaceuticals	200	89.14 million	78.71 million	Optionable
AVBP ArriVent BioPharma	40	34.21 million	27.86 million	N/A
IMTX Immatics	260	121.55 million	117.54 million	Optionable
KYTX Kyverna Therapeutics	96	43.22 million	33.71 million	Optionable

KYTX, AMLX, AVBP, and IMTX Headlines

Recent News About These Companies

Peapod Lane Capital LLC Invests $765,000 in Kyverna Therapeutics, Inc. (NASDAQ:KYTX)

July 10, 2025 | marketbeat.com

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Consensus Rating of "Buy" from Analysts

July 10, 2025 | marketbeat.com

KYVERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

July 2, 2025 | globenewswire.com

Kyverna Therapeutics Names Marc Grasso Chief Financial Officer

June 30, 2025 | marketwatch.com

Kyverna Therapeutics Announces Appointment of New Chief Financial Officer

June 30, 2025 | finance.yahoo.com

Kyverna Therapeutics (NASDAQ:KYTX) Activity Grows on Nasdaq Composite, Russell 1000

June 27, 2025 | kalkinemedia.comK

3 Promising Penny Stocks With Market Caps Over $100M

June 10, 2025 | finance.yahoo.com

Kyverna Therapeutics to Present at the Jefferies Global Healthcare Conference

May 28, 2025 | prnewswire.com

HC Wainwright & Co. Upgrades Kyverna Therapeutics (KYTX)

May 27, 2025 | msn.com

Kyverna Therapeutics: Buy Rating Backed by Promising Pipeline and Strong Financial Position

May 27, 2025 | tipranks.com

Kyverna Shareholder Sues Over Kidney Therapy Trial Data Post IPO

May 15, 2025 | news.bloomberglaw.comN

With 40% ownership, Kyverna Therapeutics, Inc. (NASDAQ:KYTX) has piqued the interest of institutional investors

May 15, 2025 | finance.yahoo.com

KYVERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

May 15, 2025 | globenewswire.com

Kyverna Therapeutics Reports Q1 2025 Progress and Outlook

May 14, 2025 | tipranks.com

Kyverna lays off 16% of staff as autoimmune CAR-T plans pick up pace

May 14, 2025 | fiercebiotech.comF

Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

May 13, 2025 | prnewswire.com

Why Kyverna Therapeutics, Inc.’s (KYTX) Stock Is Down 5.26%

May 6, 2025 | aaii.comA

Why Kyverna Therapeutics, Inc.’s (KYTX) Stock Is Down 5.19%

May 2, 2025 | aaii.comA

Why Kyverna Therapeutics, Inc.’s (KYTX) Stock Is Up 6.52%

April 17, 2025 | aaii.comA

Why Kyverna Therapeutics, Inc.’s (KYTX) Stock Is Down 5.38%

April 15, 2025 | aaii.comA

Kyverna Therapeutics price target lowered to $4 from $6 at H.C. Wainwright

April 4, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYTX, AMLX, AVBP, and IMTX Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

$8.34 +0.06 (+0.72%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$8.39 +0.05 (+0.60%)

As of 07/18/2025 07:03 PM Eastern

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

ArriVent BioPharma NASDAQ:AVBP

$22.05 -0.67 (-2.95%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$22.17 +0.12 (+0.54%)

As of 07/18/2025 04:31 PM Eastern

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Immatics NASDAQ:IMTX

$6.00 -0.21 (-3.38%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$5.86 -0.15 (-2.42%)

As of 07/18/2025 07:56 PM Eastern

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Kyverna Therapeutics NASDAQ:KYTX

$3.90 -0.17 (-4.18%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$3.88 -0.02 (-0.51%)

As of 07/18/2025 06:11 PM Eastern

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time